NCT03971201 is a Phase 2 clinical trial of hepatic resection in Hepatocellular Cancer, sponsored by White Plains Hospital.

Who is sponsoring NCT03971201?

NCT03971201 is sponsored by White Plains Hospital.

What drugs are being tested in NCT03971201?

Interventions in NCT03971201: hepatic resection, Sorafenib.

What condition does NCT03971201 study?

NCT03971201 studies Hepatocellular Cancer.

Is NCT03971201 still recruiting?

NCT03971201 is currently status unknown. Last updated 14 April 2021.

Last reviewed 2021-04-14 · How we verify

NCT03971201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Status unknown Phase 2 Last updated 14 April 2021

What this trial tests

Phase 2 trial testing hepatic resection in Hepatocellular Cancer in 200 participants. Status unknown.

Timeline

6 September 2019

Primary endpoint
31 December 2022

30 June 2023

Quick facts

Lead sponsor	White Plains Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	6 September 2019
Primary completion	31 December 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

hepatic resection
Sorafenib (SORAFENIB) — full drug profile →

Conditions studied

Hepatocellular Cancer — all drugs for Hepatocellular Cancer →

Sponsor

White Plains Hospital

Who can join

18 and older, any sex, with Hepatocellular Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with HCC with portal vein involvement not involving the bifurcation (vP1-vP3) and no evidence of extra-hepatic spread will be enrolled. Patients will be required to have Child's A liver function and no significant portal hypertension. Patients will be randomly assigned with a 1:1 ratio to either surgery followed by adjuvant sorafenib or sorafenib alone. Patients will be followed by serial imaging. The primary end-point is overall survival.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium.
Lee HA, Rim CH. · · 2020 · cited 6× · PMID 33376712 · DOI 10.2147/jhc.s285357
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.
Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, et al · · 2025 · cited 1× · PMID 40589998 · DOI 10.2147/itt.s528709

Verify or expand the search:

Other trials of hepatic resection

Trials testing the same drug.

NCT03191123 — Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor · NA · unknown

Other recruiting trials for Hepatocellular Cancer

Currently open trials in the same condition.

NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06362369 — A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · Phase 1, PHASE2 · recruiting
NCT05451043 — Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabili · Phase 2 · recruiting
NCT05701488 — SIRT With Tremelimumab and Durvalumab for Resectable HCC · Phase 1 · recruiting
NCT05185505 — Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria · Phase 4 · recruiting

Other White Plains Hospital trials

Trials by the same sponsor.

NCT06830135 — Telehealth Approach to Enhancing Glycemic Control · NA · not yet recruiting
NCT04293211 — Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Plac · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03971201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by White Plains Hospital
Last refreshed: 14 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03971201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing